Department of Medicine, Division of Allergy and Clinical Immunology, Winthrop University Hospital, USA.
Mult Scler. 2011 Feb;17(2):250-3. doi: 10.1177/1352458510388966. Epub 2010 Dec 21.
Induction of tolerance protocols have been applied successfully to manage allergic reactions to many medications. Hypersensitivity reactions to natalizumab (TYSABRI®) have been recognized as a growing problem. In circumstances where a hypersensitivity reaction to a medication has occurred, but no suitable alternative exists, drug induction of tolerance protocols may be considered. Drug induction of tolerance protocols were performed in three patients with prior hypersensitivity reactions to natalizumab. All three patients tolerated the protocol without adverse reactions, allowing for the safe reintroduction of natalizumab. To conclude, this case series demonstrates success with an induction of tolerance procedure to a highly effective biological agent for multiple sclerosis, in patients with allergic reactions to natalizumab.
诱导耐受方案已成功应用于治疗许多药物的过敏反应。对那他珠单抗（TYSABRI®）的过敏反应已被认为是一个日益严重的问题。在发生药物过敏反应但又没有合适替代药物的情况下，可以考虑使用药物诱导耐受方案。本研究对 3 例曾对那他珠单抗过敏的患者进行了药物诱导耐受方案。所有 3 例患者均耐受该方案，无不良反应，从而安全地重新引入那他珠单抗。总之，本病例系列研究显示，在对那他珠单抗过敏的多发性硬化症患者中，诱导耐受方案对一种高效的生物制剂有效。
